DERM Valuation

Journey Medical Corp

Add to Watchlist

Advanced Chart

7.470

+0.39(5.508%)1D

Overview
Forecast
Valuation
Earnings

DERM Relative Valuation

DERM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DERM is overvalued; if below, it's undervalued.

Historical Valuation

Journey Medical Corp (DERM) is now in the Overvalued zone, suggesting that its current forward PS ratio of 1.93 is considered Overvalued compared with the five-year average of -1.60. The fair price of Journey Medical Corp (DERM) is between 2.70 to 6.19 according to relative valuation methord. Compared to the current price of 7.48 USD , Journey Medical Corp is Overvalued By 20.84%.

Relative Value

Fair Zone

2.70-6.19

Current Price：7.48

20.84%

Overvalued

27.62

Trailing

Forward

8.38

EV/EBITDA

Journey Medical Corp. (DERM) has a current EV/EBITDA of 8.38. The 5-year average EV/EBITDA is 12.72. The thresholds are as follows: Strongly Undervalued below -44.63, Undervalued between -44.63 and -15.95, Fairly Valued between 41.40 and -15.95, Overvalued between 41.40 and 70.07, and Strongly Overvalued above 70.07. The current Forward EV/EBITDA of 8.38 falls within the Historic Trend Line -Fairly Valued range.

23.88

EV/EBIT

Journey Medical Corp. (DERM) has a current EV/EBIT of 23.88. The 5-year average EV/EBIT is -3.97. The thresholds are as follows: Strongly Undervalued below -27.85, Undervalued between -27.85 and -15.91, Fairly Valued between 7.96 and -15.91, Overvalued between 7.96 and 19.90, and Strongly Overvalued above 19.90. The current Forward EV/EBIT of 23.88 falls within the Strongly Overvalued range.

1.93

Journey Medical Corp. (DERM) has a current PS of 1.93. The 5-year average PS is 1.17. The thresholds are as follows: Strongly Undervalued below 0.04, Undervalued between 0.04 and 0.60, Fairly Valued between 1.73 and 0.60, Overvalued between 1.73 and 2.29, and Strongly Overvalued above 2.29. The current Forward PS of 1.93 falls within the Overvalued range.

0.00

P/OCF

Journey Medical Corp. (DERM) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.44. The thresholds are as follows: Strongly Undervalued below -9.97, Undervalued between -9.97 and -5.70, Fairly Valued between 2.83 and -5.70, Overvalued between 2.83 and 7.09, and Strongly Overvalued above 7.09. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

162.83

P/FCF

Journey Medical Corp. (DERM) has a current P/FCF of 162.83. The 5-year average P/FCF is 4.09. The thresholds are as follows: Strongly Undervalued below -55.72, Undervalued between -55.72 and -25.82, Fairly Valued between 33.99 and -25.82, Overvalued between 33.99 and 63.89, and Strongly Overvalued above 63.89. The current Forward P/FCF of 162.83 falls within the Strongly Overvalued range.

Journey Medical Corp (DERM) has a current Price-to-Book (P/B) ratio of 8.62. Compared to its 3-year average P/B ratio of 704.56 , the current P/B ratio is approximately -98.78% higher. Relative to its 5-year average P/B ratio of 557.74, the current P/B ratio is about -98.45% higher. Journey Medical Corp (DERM) has a Forward Free Cash Flow (FCF) yield of approximately -1.57%. Compared to its 3-year average FCF yield of -15.09%, the current FCF yield is approximately -89.60% lower. Relative to its 5-year average FCF yield of -12.11% , the current FCF yield is about -87.03% lower.

8.63

P/B

Median3y

704.56

Median5y

557.74

-1.57

FCF Yield

Median3y

-15.09

Median5y

-12.11

Competitors Valuation Multiple

The average P/S ratio for DERM's competitors is 0.95, providing a benchmark for relative valuation. Journey Medical Corp Corp (DERM) exhibits a P/S ratio of 1.93, which is 101.95% above the industry average. Given its robust revenue growth of 1.04%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Eledon Pharmaceuticals Inc

Loss

155.69M

IRWD.O

Ironwood Pharmaceuticals Inc

Actuate Therapeutics Inc

Loss

173.43M

ENTA.O

Enanta Pharmaceuticals Inc

3.12

1.91%

188.77M

Performance Decomposition

Market capitalization of DERM increased by 50.00% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -12.97 to -17.80.

The secondary factor is the Margin Expansion, contributed 11.75%to the performance.

Overall, the performance of DERM in the past 1 year is driven by P/E Change. Which is more unsustainable.

1.04%

14.86M → 15.01M

Revenue Growth

11.75%

-22.63 → -25.29

Margin Expansion

37.21%

-12.97 → -17.80

P/E Change

50.00%